Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 10;25(23):7024–7034. doi: 10.1158/1078-0432.CCR-19-1372

Figure 3. Serial Plasma-Based Overall Survival Analysis for Patients Treated with Immune Checkpoint Blockade.

Figure 3.

(A) Evaluation of overall survival with the protein biomarker level at last dose (CA125, CEA, CA19–9, or PSA). A significant inverse correlation was observed between the overall survival in months when compared to the residual protein biomarker (r=-0.67, p=<0.001; Pearson correlation). (B) Kaplan-Meier curves for overall survival among patients with tissue enrollment status of MSI and detectable protein biomarker levels (n=45). For patients with two consecutive timepoints with >75% reduction in protein biomarker levels, landmarked 3.5–7 weeks post treatment initiation (n=12), median overall survival was not reached. For patients with ≤75% reduction in protein biomarker levels (n=33), median overall survival was 35.1 months. (C) Evaluation of overall survival compared to residual MSI allele levels at last dose. A significant inverse correlation was observed between the overall survival when compared to the residual MSI allele levels (r=-0.91, p=<0.001; Pearson correlation). (D) Kaplan-Meier curves for overall survival among patients with tissue enrollment status of MSI and detectable MSI status at baseline (n=9). For patients with two consecutive timepoints displaying no residual MSI alleles (n=4) median overall survival was not reached. For patients with multiple timepoints containing residual MSI alleles (n=5) median overall survival was 7.64 months. (E) Evaluation of overall survival compared to residual TMB levels at last dose. A significant inverse correlation was observed between the overall survival in months when compared to the residual TMB levels (r=-0.95, p=<0.001; Pearson correlation). (F) Kaplan-Meier curves for overall survival among patients with tissue enrollment status of MSI and detectable TMB levels at baseline (n=11). For patients with >90% reduction in TMB levels (n=4), median overall survival was not reached. For patients with ≤90% reduction in TMB levels (n=7), median overall survival was 7.64 months. “/” indicates a censored datapoint; “*” indicates cases where baseline protein biomarker, MSI or TMB was not detected and were not included in the subsequent analyses; In cases where residual protein biomarker, MSI or TMB levels increased when compared to baseline, values of greater than 100% are indicated.